Will the results of the ACCOMPLISH trial affect the recommendations of JNC 8?

Journal of Clinical Hypertension

Volumn 11, Issue 2, 2009, Pages 100-101

  Cohen, Debbie L ^a   Townsend, Raymond R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEATH; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MEDICAL DECISION MAKING; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; STROKE; TREATMENT OUTCOME;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 60549091199     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00075.x     Document Type: Note

References (8)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289(19):2560-2572.
2. Jamerson K, Weber MA, Bakris GL, et al; for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrchlorthiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-2428.
3. Mason RP. A rationale for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118(suppl 12A):54-61.
4. Luscher TF, Wenzel RR, Moreau P, et al. Vascular protective effects of ACE inhibitors and calcium antagonists: Theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther. 1995;9 (suppl 3):509-523.
5. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 2006;47: 636-642.
6. Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: An unexpected mechanism of action of a calcium channel-blocking agent. Circulation. 1998;97:576-580.
7. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens. 2004;17:37-42.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.